Comparative Pharmacology
Head-to-head clinical analysis: TESTODERM versus TESTOSTERONE CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTODERM versus TESTOSTERONE CYPIONATE.
TESTODERM vs TESTOSTERONE CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy: binds to androgen receptors, activating gene transcription for protein synthesis and muscle growth.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
One to two 2.5 mg or 5 mg patches applied to clean, dry, intact skin of the back, abdomen, upper arms, or thighs once daily (approximately every 24 hours).
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 10-100 minutes for free testosterone in plasma; for total testosterone (including bound), the apparent half-life ranges from 2-4 hours after transdermal application, with significant interindividual variability.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Primarily renal (approximately 90% as glucuronide and sulfate conjugates, <10% as unchanged testosterone); about 6% is excreted in feces via biliary elimination.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Category C
Category D/X
Androgen
Androgen